Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    Patient safety
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    September 28, 2022
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    Radiation therapy
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    August 19, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Adverse events

    Text-Messaging Prescreening Streamlines Treatment Visits and Care for ICI Toxicities
    Adverse events

    Text-Messaging Prescreening Streamlines Treatment Visits and Care for ICI Toxicities

    Prescreening patients for immune-related adverse events during treatment with immune checkpoint inhibitors using text messaging may reduce the need for some in-person, preinfusion office visits, researchers reported in JAMA Network Open. The approach may help decrease the burden of cancer care for both patients and providers.

    January 11, 2023
    Studies Show Best Practices to Manage CAR T-Cell Therapies’ irAEs and Improve Outcomes
    Immunotherapy

    Studies Show Best Practices to Manage CAR T-Cell Therapies’ irAEs and Improve Outcomes

    Rapid advancements in the science of chimeric antigen receptor (CAR) T-cell therapies present unique challenges and opportunities related to patient care. Nurses are at the forefront of those advancements—contributing to practice guidelines, developing center-specific protocols, publishing outcomes and best practices, and researching the patient experience, outcomes, and supportive interventions.

    May 09, 2022
    ONS Bridge

    Don’t Delay When Managing irAEs From Immune Checkpoint Inhibitors

    To prevent life-threatening complications that could affect treatment adherence and outcomes, oncology nurses must be vigilant in early recognition and treatment of immune-related adverse events (irAEs), Lisa A. Kottschade, MSN, APRN, CNP, from Mayo Clinic in Rochester, MN, said during a session held at the ONS BridgeTM virtual conference on September 14, 2021. She provided an overview of what to watch for and nursing considerations for common irAEs.

    September 14, 2021
    Long-Term irAEs From Checkpoint Inhibitors Have Considerations for Survivorship
    Research

    Long-Term irAEs From Checkpoint Inhibitors Have Considerations for Survivorship

    More than 40% of patients with melanoma treated with nivolumab or pembrolizumab experience persistent long-term immune-related adverse events (irAEs) for at least 1.5 years, researchers reported in JAMA Oncology.

    July 14, 2021
    Nurse Research AIMS to Increase Screening for Malnutrition and Reduce Bowel Dysfunction
    Oncology nurse researcher

    Nurse Researcher AIMS to Increase Screening for Malnutrition and Reduce Bowel Dysfunction

    Research has identified an association between malnutrition and functional deficits in patients with cancer, regardless of age, and other studies confirm that malnutrition affects treatment tolerability, outcomes, and quality of life for patients with cancer. However, studies have also found that oncology clinicians do not consistently assess for malnutrition and functional deficits in clinical settings. 

    July 13, 2021
    The Case of the CIA-Combatting Combination
    Clinical practice

    The Case of the CIA-Combatting Combination

    Sofia is a 35-year-old patient who identifies as female who was recently diagnosed with breast cancer and is concerned with experiencing chemotherapy-induced alopecia (CIA) as an adverse event from treatment. She comes in for her first infusion of adriamycin plus cyclophosphamide and is using scalp cooling to prevent hair loss. She works as a project manager, which requires her to keep her camera on for her many daily video calls. She is very anxious about losing her hair and asks you if taking minoxidil in addition to the scalp cooling treatment would guarantee she maintains her hair. 

    June 25, 2021
    Adverse events

    Here’s Why Oncology Nurses Are Pivotal in Managing Immune-Related Adverse Events

    Immune checkpoint inhibitors (ICPIs) mobilize the body’s own immune system to target cancer cells. However, the resulting immune-related adverse events (irAEs) vary in severity and may persist for months or years following treatment.

    April 29, 2021
    ONS Congress

    Oncology Nurses Navigate the Changing Landscape of Immuno-Oncology

    Immune checkpoint inhibitors (ICPIs) enhance treatment response while minimizing toxicities for patients with cancer. However, education is key to managing the therapies’ unique adverse events (AEs). During a session for the ONS 46th Annual Congress™, Marianne Davies, DNP, ACNP, FAAN, of the Yale Comprehensive Cancer Center, Smilow Cancer Hospital at Yale New Haven Hospital, and the Yale University School of Nursing, and Laura S. Wood, RN, MSN, OCN®, of Cleveland Clinic Cancer Center, provided oncology nurses with a foundation for evaluating and grading AEs in immuno-oncology.

    April 22, 2021
    ONS Members See Beyond Barriers and Understand Benefits of Guidelines
    Research

    ONS Members See Beyond Barriers and Understand Benefits of Guidelines

    I am a clinician in my heart and soul. I was an ONS charter member and one of the first nurse practitioners (NPs) at Memorial Sloan Kettering Cancer Center in New York, NY, before any NP laws were in place and before colony-stimulating factors. The inability to prevent death secondary to chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) haunted me and led me to conduct several funded studies. 

    April 19, 2021
    Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer
    Adverse events

    Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer

    Once patients stop responding to platinum-based chemotherapy for locally advanced or metastatic urothelial cancer, their treatment options had been somewhat limited: PD-1/PD-L1 inhibitors were effective in only 13%–29% of patients and taxanes in only 11%–13%. When the antibody drug conjugate enfortumab vedotin was approved in late 2019, it offered new hope for patients and providers, with clinical trials reporting a 44% objective response rate.

    April 13, 2021
    Zydus Pharmaceuticals Inc. Issues Voluntary Nationwide Recall of Acyclovir Sodium Injection
    Clinical practice

    Zydus Pharmaceuticals Inc. Issues Voluntary Nationwide Recall of Acyclovir Sodium Injection

    On March 25, 2021, the U.S. Food and Drug Administration shared Zydus Pharmaceuticals Inc.’s notice of its voluntary recall of four lots of acyclovir sodium injection 50 mg/ml, supplied in 10 ml and 20 ml vials, after receiving reports of crystallization in the product.

    March 29, 2021
    The Case of the Cord Blood Match
    Clinical practice

    The Case of the Cord Blood Match

    Zhang is a 67-year-old man who had no history of medical concerns until he was hospitalized for pneumonia. A complete blood count taken during his workup for pneumonia showed pancytopenia, and a biopsy confirmed a diagnosis of acute myeloid leukemia. After multiple rounds of induction therapy, Zhang's bone marrow biopsy showed minimal residual disease and he entered remission. His oncologist recommends an allogeneic hematopoietic stem cell transplant as soon as possible because of the disease's aggressive nature, but he has no match in the registry. 

    March 26, 2021
    Management Strategies for Cutaneous Toxicity From EGFR Inhibitors
    Advanced Practice Nursing (APRN)

    Management Strategies for Cutaneous Toxicity From EGFR Inhibitors

    Epidermal growth factor receptor (EGFR)-targeted therapy is effective for several solid tumor malignancies, primarily non-small cell lung cancer with EGFR mutation and metastatic colorectal cancer. Although the agents spare patients from typical side effects seen with more conventional cytotoxic chemotherapies, such as nausea or vomiting, they do have a unique side-effect profile, including potentially dose-limiting cutaneous toxicity. 

    March 11, 2021
    Manage Adverse Events From PI3K Inhibitors for Breast Cancer
    Breast cancer

    Manage Adverse Events From PI3K Inhibitors for Breast Cancer

    In 2019, PI3K inhibitors became a new treatment option for postmenopausal women and men with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer with the U.S. Food and Drug Administration’s approval of alpelisib in combination with fulvestrant. Although alpelisib remains the only PI3K inhibitor approved today, others are in clinical trials, and the new class of agents has a unique safety profile.

    March 09, 2021
    The Case of the Targeted Therapy Toxicities
    Clinical practice

    The Case of the Targeted Therapy Toxicities

    Three years ago, Tony, a 42-year-old man, began FOLFOX chemotherapy treatment for stage III colon cancer and achieved a complete response. Two years later, a biopsy of an intraabdominal lesion uncovered metastatic disease, and he was prescribed the epidermal growth factor inhibitor (EGFRi) cetuximab. Alex, the oncology nurse educating Tony on the side effects of EGFRi therapy, understands that skin toxicities are common with the class of drugs and looks for national guidelines for prevention and management direction.

    January 19, 2021
    What the Evidence Says for Guided Imagery in Oncologic Care
    Complementary therapy

    What the Evidence Says About Guided Imagery in Oncologic Care

    Imagery is a mind-body practice with deep historical roots. It uses imagination to recreate mental images, sounds, smells and even tastes to help achieve relaxation and to promote healing. Guided imagery can be learned in an interactive manner from a licensed practitioner or from books and self-help tapes. Repeating the practice results in a conditioning effect that can empower the individual to use it whenever needed.

    January 18, 2021
    Manage Cancer Treatment-Related Radiodermatitis With ONS Guidelines™
    Clinical practice guidelines

    Manage Cancer Treatment-Related Radiodermatitis With ONS Guidelines™

    Painful skin reactions may develop in as many as 95% of patients receiving radiotherapy treatments for cancer. Patients report that it affects their quality of life and that purchasing interventions to soothe their skin increases their out-of-pocket costs. Supporting patients who experience the side effect is critical for their well-being.

    January 12, 2021
    Sunstar Americas, Inc., Expands Voluntary Nationwide Recall of Paroex® Chlorhexidine Gluconate Oral Rinse USP, 0.12%, for Microbial Contamination
    U.S. Food and Drug Administration (FDA)

    Sunstar Americas, Inc., Expands Voluntary Nationwide Recall of Paroex® Chlorhexidine Gluconate Oral Rinse USP, 0.12%, for Microbial Contamination

    On December 28, 2020, the U.S. Food and Drug Administration announced that Sunstar Americas, Inc., expanded its October 27, 2020, voluntary recall of Paroex® chlorhexidine gluconate oral Rinse USP, 0.12%, because of possible contaminated with the bacteria Burkholderia lata.

    January 06, 2021
    What the Evidence Says for Cannabis in Cancer Care
    Complementary therapy

    What the Evidence Says About Cannabis in Cancer Care

    An annual flowering herb native to East Asia, Cannabis sativa is cultivated around the world. It is used in traditional medicine as an analgesic, hypnotic, hallucinogenic, sedative, and anti-inflammatory. Preparations derived from its flowers, leaves, and hashish made from its resinous extract are taken orally, by smoking, or by vaporizing. Cannabis teas, tinctures, ointments, and oil-based extracts that can be mixed into food products are also popular.

    September 28, 2020
    ONS Bridge

    Nurses Are Critical to Recognizing Adverse Events From Immune Checkpoint Inhibitors

    Although immune checkpoint inhibitors can be highly effective cancer treatments, potentially even curative in several disease states, they can cause immune-related adverse events in any tissue or organ system, presenters said in a session at the inaugural ONS Bridge™ virtual conference.

    September 15, 2020
    ONS Bridge

    Develop a Standard Approach to Recognize Lab Abnormalities and Adverse Events With Immune Checkpoint Inhibitors

    By harnessing the power of a patient’s own immune system, immune checkpoint inhibitors improve antitumor immunity by blocking negative regulators (checkpoints) of T-cell function that exist on both immune and tumor cells. They essentially stop the immune system from turning off before cancer is completely eliminated.

    September 15, 2020
    ONS Bridge

    Oncology Symptom Science Research Needs to Focus on New Therapies

    Immunotherapy, emerging therapies, precision health, and biosignatures are the next frontier for oncology symptom science research, specifically patient-reported outcomes and immune-related adverse events, researchers reported during a presentation on September 8, 2020, at the inaugural ONS Bridge™ virtual conference.

    September 08, 2020
    FDA Designates Majority of BD’s June 30 Alaris Pump Recall as Class I
    U.S. Food and Drug Administration (FDA)

    FDA Designates Majority of BD’s June 30 Alaris Pump Recall as Class I

    On September 1, 2020, the U.S. Food and Drug Administration (FDA) designated three of the situations involved in BD’s June 30, 2020, previously announced voluntary recall of several models of its Alaris™ system as class I recalls. Class I recall designation indicates a reasonable probability that the use of the product will cause serious adverse health consequences or death.

    September 02, 2020
    Manage Immune-Related Adverse Events in Patients on Durvalumab
    Adverse events

    Manage Immune-Related Adverse Events in Patients on Durvalumab

    Durvalumab immunotherapy became a new standard of care for patients with stage III unresectable non-small cell lung cancer whose disease did not progress following two cycles of platinum-based chemoradiotherapy after its approval in February 2018, and in March 2020, its indication was expanded for use as first-line treatment in patients with extensive-stage small cell lung cancer as well. Key to keeping patients on immunotherapy treatment and giving them the best chance at long-term survival is effective management of immune-related adverse events.

    August 11, 2020
    The Case of the Thyroid Tradeoff
    Clinical practice

    The Case of the Thyroid Tradeoff

    Tesla is a 24-year-old woman diagnosed with stage IIIA Hodgkin lymphoma. She enrolled in a clinical trial where she received a combination of chemotherapy and immunotherapy with pembrolizumab, an anti-PD-1 antibody. The clinical trial protocol required three doses every three weeks. At baseline, her thyroid function tests were normal. When she presented for her third dose, her labs showed grade 2 hyperthyroidism.

    July 17, 2020
    Immune-Related Adverse Events With PD-1 Inhibitors in Head and Neck Cancer
    Clinical practice

    Immune-Related Adverse Events With PD-1 Inhibitors in Head and Neck Cancer

    Clinical trial results show that PD-1 inhibitors offer improved survival and a better safety profile compared to standard, single-agent chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. However, because of their mechanism of action as immunotherapy, patients receiving the agents may experience immune-related adverse events (irAEs).

    February 11, 2020
    Evidence-Based Program Reduced C. Difficile Incidence in Patients With Cancer
    Clinical practice

    Evidence-Based Program Reduced C. Difficile Incidence in Patients With Cancer

    Clostridium difficile infection is a dangerous and sometimes deadly adverse event in immunocompromised patients with cancer. Although transmission risk is high in the hospital setting, even with isolation precautions, oncology providers can use a variety of prevention techniques to reduce the chance for infection in their patients.

    December 10, 2019
    irAEs Linked to Improved Benefit From Pembrolizumab
    Immunotherapy

    irAEs Linked to Improved Benefit From Pembrolizumab

    Patients with advanced melanoma who received adjuvant therapy with pembrolizumab and subsequently developed immune-related adverse events (irAEs) saw a 63% reduced risk of recurrence, compared to 44% for those who did not develop irAEs. The study findings were presented at the 2019 American Society of Clinical Oncology annual meeting.

    October 09, 2019
    FDA Warns of Rare Lung Inflammation With Certain CDK 4/6 Inhibitors
    U.S. Food and Drug Administration (FDA)

    FDA Warns of Rare Lung Inflammation With Certain CDK 4/6 Inhibitors

    Palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) used to treat some patients with advanced breast cancers may cause rare but severe inflammation of the lungs, the U.S. Food and Drug Administration (FDA) announced on September 13, 2019. It approved new warnings about the risk on the prescribing information and package insert for the entire class of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor medicines. However, “the overall benefit of CDK 4/6 inhibitors is still greater than the risks when used as prescribed,” the agency noted.

    September 13, 2019
    Immunotherapy Experts Identify Key Oncology Nursing Priorities at ONS Summit
    Immunotherapy

    Immunotherapy Experts Identify Key Oncology Nursing Priorities at ONS Summit

    Care coordination, appropriate adverse event assessment and treatment, and rapid, continuous learning are essential priorities for oncology nurses to care for patients receiving immunotherapy, according to the experts who participated in ONS’s immunotherapy summit in March 2018. 

    August 13, 2019
    Manage Immunotherapy-Related Diarrhea and Colitis
    Advanced Practice Nursing (APRN)

    Manage Immunotherapy-Related Diarrhea and Colitis

    Although immunotherapy has a unique set of toxicities compared to traditional chemotherapy, in general, grade 3 or 4 toxicities are rare—with the exception of grade 3 diarrhea and colitis. The mechanisms by which immune-related diarrhea and colitis occur are not clear. However, T-cell activation leads to high levels of CD4 T-helper cell cytokines and cytolytic CD8 T-cell tissue infiltration. Some research suggests that depleting regulatory T cells also induces autoimmunity.

    June 06, 2019
    The Case of the Terrible Toxicities
    Adverse events

    The Case of the Terrible Toxicities

    After completing neoadjuvant chemotherapy for triple-negative invasive breast cancer, Madeline, age 32, had a bilateral mastectomy with reconstructive surgery. Final pathology showed residual disease in the breast and one lymph node, and her oncologist recommended adjuvant therapy with capecitabine (1,500 mg twice a day for 14 days, off for 7 days). Five weeks postoperatively, she started cycle 1. Eight days later, her husband called the cancer clinic reporting that over the past two days, his wife developed profound weakness, unremitting diarrhea despite using diphenoxylate and atropine as directed, and painful, red, swollen hands and feet. Her symptoms represented a drastic change from her usual routine and energy level.

    May 14, 2019
    How APRNs Can Manage Immunotherapy-Related Hypophysitis in Patients With Cancer
    Advanced Practice Nursing (APRN)

    How APRNs Can Manage Immunotherapy-Related Hypophysitis in Patients With Cancer

    Immunotherapy may place patients at risk for distinctive toxicities that differ from traditional chemotherapy. One example is endocrine dysfunction, including hypophysitis, hypo- or hyperthyroidism, type 1 diabetes, and primary adrenal insufficiency. 

    April 25, 2019
    ONS Congress

    Resources Are Available to Guide Management of Immunotherapy-Related Adverse Events

    Immunotherapy has evolved into the “fourth pillar” of cancer care, along with surgery, chemotherapy and radiation therapy, according to Laura S. Wood RN, MSN, OCN®, of the Cleveland Clinic Taussig Cancer Center in Ohio and Krista M. Rubin, MS, RN, FNP-BC, of Massachusetts General Hospital in Boston, who spoke during a session on Wednesday, April 10, 2019, at the ONS 44th Annual Congress in Anaheim, CA. Immunotherapeutic agents, however, are vastly different from chemotherapies and have a distinct toxicity profile that advanced practice nurses must be familiar with.

    April 10, 2019
    For Oxaliplatin Hypersensitivity Reactions, Prevention Is the Best Strategy, but Here’s How to Manage Them
    Adverse events

    For Oxaliplatin Hypersensitivity Reactions, Prevention Is the Best Strategy, but Here’s How to Manage Them

    As the use of oxaliplatin in the treatment of gastrointestinal, gynecologic, and other cancers continues to grow, so too does the incidence of hypersensitivity reactions connected to the drug. Because the development of HSRs may require patients to discontinue oxaliplatin even if it’s effective against their cancer, oncology nurses need to be able to prevent or minimize reactions whenever possible.

    April 09, 2019
    How APRNs Can Manage Immunotherapy-Related Hypothyroidism in Patients With Cancer
    Advanced Practice Nursing (APRN)

    How APRNs Can Manage Immunotherapy-Related Hypothyroidism in Patients With Cancer

    Immunotherapy has a unique set of toxicities in comparison to traditional chemotherapy. Endocrine dysfunction, including hypo- or hyperthyroidism, hypophysitis, type-1 diabetes, and primary adrenal insufficiency, may occur. Advanced practice RNs (APRNs) have a role in monitoring and treating patients for endocrine-related toxicities.

    February 21, 2019
    Manage Afatinib’s Adverse Events to Keep Patients on Treatment
    Adverse events

    Manage Afatinib’s Adverse Events to Keep Patients on Treatment

    Ongoing therapy with afatinib—an oral, irreversible ErbB family blocker—for as long as it is effective and tolerable is considered first-line treatment for metastatic non-small cell lung cancer in patients with EGFR mutations. In their article in the October 2018 issue of the Clinical Journal of Oncology Nursing, Edwards, Adan, Lalla, Lacouture, O’Brien, and Sequist discussed the most common adverse events (AEs) associated with afatinib and their real-life experiences managing them in clinical practice to keep patients on therapy.

    December 11, 2018
    San Antonio Breast Cancer Symposium

    Highly Emetogenic Chemotherapy Still Contributes to Potentially Avoidable Adverse Events

    The Centers for Medicare and Medicaid Services (CMS) implemented an oncology outcome measure to assess the quality of care and determine outpatient hospital payment (OP-35: Admissions and Emergency Department Visits for Patients Receiving Outpatient Chemotherapy). The measure assesses 30-day postchemotherapy rates of inpatient or emergency department (ED) events deemed “potentially avoidable” because of an association with any of the 10 CMS-defined toxicities: anemia, dehydration, diarrhea, fever, nausea, emesis, neutropenia, pain, pneumonia, or sepsis. Researchers sought to assess those events when linked to highly emetogenic chemotherapy (HEC) in patients treated with anthracycline plus cyclophosphamide (AC), carboplatin, or cisplatin. They presented the findings at the San Antonio Breast Cancer Symposium on December 7, 2018.

    December 07, 2018
    JADPRO Live

    Infusion Technique Reduces AEs in Patients With ALL Receiving PEG-Asparaginase

    Asparaginase is part of treatment for acute lymphocytic leukemia (ALL) and is associated with improved outcomes in those who complete this course of treatment. Despite the necessity of PEG-asparaginase, 20%–30% of patients can experience toxicities.

    November 02, 2018
    Using CTCAE to Report Immunotherapy Adverse Events
    Adverse events

    Using CTCAE to Report Immunotherapy Adverse Events

    Although immunotherapy is changing the face of cancer care, it’s not exempt from side effects. As researchers and clinicians work to understand immune-related adverse events and how to manage them, a new challenge is emerging: reporting and grading them to get an accurate grasp on incidence rates and to standardize care to ensure better outcomes for patients. The Common Terminology Criteria for Adverse Events (CTCAE) is one tool that’s helping researchers and bedside nurses do just that. 

    August 01, 2018
    The Oncology Nurse Experience in Managing Adverse Events in Patients Receiving Ibrutinib
    Adverse events

    The Oncology Nurse Experience in Managing Adverse Events in Patients Receiving Ibrutinib

    Ibrutinib is a first-in-class Bruton’s tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). The drug’s approval was based on results from the multicenter, open-label, phase III RESONATE trial.

    July 25, 2018
    CDK 4/6 Adverse Events
    Adverse events

    The Case of the CTCAE Assessment for CDK4/6 Adverse Events

    Mrs. Jones is a 66-year-old postmenopausal woman who developed left breast pain and a palpable mass. A mammogram and ultrasound showed a 4.6 cm mass with an enlarged axillary node. A core biopsy revealed invasive ductal carcinoma that is estrogen receptor positive, progesterone receptor positive, and HER2 negative. Positron-emission tomography and computed tomography scans revealed metastatic disease.

    June 19, 2018
    ONS Congress

    Managing Immunotherapy-Related Adverse Events

    Immunotherapy is becoming an important role in cancer care and having an understanding of immune-related adverse events (irAEs) is critical for oncology nurses to provide safe and effective patient care. Rowena Schwartz, PharmD, BCOP, of the University of Cincinnati in Ohio, discussed strategies for managing these AEs during a session at the 43rd Annual Congress in Washington, DC.

    May 19, 2018
    Supporting Second Victims Will Make Your Practice Safer
    Safety

    Supporting Second Victims Will Make Your Practice Safer

    Adverse events and traumatic moments send shockwaves through the entire care team. As families grieve the loss of a loved one, providers can often suffer from feelings of overwhelming guilt, remorse, or helplessness. When clinicians struggle with the aftermath of a tragic care event, they become known as second victims. Second victim experiences can lead to lapses in safety and care and could be potentially dangerous for future patients.

    April 12, 2018
    ONS Members Help Define Checkpoint Inhibitor Adverse Event Guidelines
    Immunotherapy

    ONS Members Help Define Checkpoint Inhibitor Adverse Event Guidelines

    Because the treatment of symptoms, side effects, and adverse events associated with immunotherapies can differ greatly from the standard of care, the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN)—along with experts from ONS staff and membership—collaborated to develop guidelines to inform clinicians about managing immune-related adverse events associated with checkpoint inhibitor therapy.

    March 16, 2018
    sepsis awareness
    Adverse events

    September Is Sepsis Awareness Month

    As September winds down, ONS, a partner in the Centers for Disease Control and Prevention’s (CDC’s) and American Nurses Association’s Nursing Infection Control Education Network, is raising awareness of Sepsis Awareness Month by highlighting resources and strategies for oncology nurses who are deeply rooted in preventing and treating sepsis in patients with cancer.

    September 25, 2017
    Adverse Events From Immunotherapy
    Immunotherapy

    Manage Adverse Events From Immunotherapy and Targeted Therapy for Melanoma

    New targeted and immunotherapy drug approvals have offered improved survival and disease outcomes for patients with melanoma, but the new therapies are also associated with a range of adverse events (AEs) that differ from those associated with chemotherapy. Oncology nurses will need to shift their thinking to best manage those AEs.

    September 12, 2017
     Addressing Hypersensitivity Reactions to Chemotherapy
    Safety

    Time Is Short When Addressing Hypersensitivity Reactions to Chemotherapy

    Between administering antineoplastic agents, monitoring patient vitals, and preparing patients for treatment, oncology nurses are required to balance their attention between many intricate tasks. Chief among the division of duties is that oncology nurses closely monitor their patients for hypersensitivity reactions (HSRs) to prescribed agents.

    August 17, 2017
    ONS Congress

    Palonosetron HCL Is a Preferred Treatment for Moderately Emetogenic Chemotherapies

    Chemotherapy-induced nausea and vomiting (CINV) is an adverse event (AE) associated with cancer therapies that healthcare providers often underestimate. CINV can interfere with treatment compliance and adherence, and patients who experienced CINV in the first cycle of chemotherapy are almost four times more likely to experience it during subsequent treatment cycles.

    July 02, 2017
    Critical Care for Patients With Cancer
    Clinical practice

    Critical Care for Patients With Cancer

    Five to Ten Percent of patients with cancer will need to visit the intensive care unit (ICU) for a life-threatening condition. In fact, estimates suggest that nearly 30% of patients with esophageal cancer or acute leukemia and those undergoing allogenic stem cell transplantation will need ICU care.

    July 01, 2017
    • Current page 1
    • Page 2
    • Next page
    • Last page Last »
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲